Advance Science & Medicine by Connecting Patients to Life-Saving Therapeutics

📨 Email dave@doubleblindbio.co to apply

<aside> 💡

Why Double Blind Bio (DBB)?

We Accelerate the Development of Next Generation Medicines

We move fast

Work with Life Sciences Experts

</aside>

About Us

Double Blind Bio automates administrative tasks, allowing clinical staff to focus on what matters most: patient care and advancing science. We’re building a future where clinical trials operate more autonomously by connecting sites, sponsors, and their data using AI. Our mission is to accelerate the delivery of cutting-edge therapeutics from development to market by building intelligent software that streamlines clinical trial operations.

To date, we’ve raised over $7 million in funding from our co-lead investors, SignalFire and Define Ventures, to accelerate this vision. Currently, we’re used by over 200 clinical research sites and have a handful of sponsor customers.

The Vision

We exist to accelerate scientific development and improve human well-being by increasing the efficacy of medicines worldwide. Today, bringing a drug to market takes over 10 years and $1-2 billion, with clinical trials consuming the bulk of the time and resources, not drug discovery.

Imagine if you could cut the time and/or cost of running a clinical trial in half. According to the Jevons paradox, as costs drop, demand for running clinical trials would rise, allowing more candidate therapies and more niche treatments to be tested and to reach the market. Clinical trial operations sit at the center of this and are the problem Double Blind Bio is solving for.

What You’ll Do

Who You Are